US Hemiplegic Migraine Market

ID: MRFR/HC/16511-CR
100 Pages
Satyendra Maurya
Last Updated: January 13, 2026
US Hemiplegic Migraine Market Research Report By Type (Familial Hemiplegic Migraine, Sporadic Hemiplegic Migraine) By End-user (Hospitals & Clinics, Diagnostic Centers, Others) By Treatment (Acute treatment, Triptans, Ergotamines, NSAIDs, Antiemetics, Narcotic Analgesics, Others) By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Others) By Preventive Treatment (Antidepressants, Botox Injections, Others) - Growth & Industry Forecast 2025 To 2035
US Hemiplegic Migraine Market

Market Size

Forecast Period2025 - 2035
CAGR (2025 - 2035)3.61%
2024 Market Size$ 0.28 Million
2025 Market Size$ 0.29 Million
2035 Market Size$ 0.42 Million

Key Players

Amgen
Teva Pharmaceutical Industries
Eli Lilly and Company
Novartis
Pfizer
AstraZeneca
Trends
  • Increased Awareness and Diagnosis
  • Advancements in Treatment Options
  • Telemedicine Integration
Opportunities
  • Growing Research and Clinical Trials
  • Rising Incidence of Hemiplegic Migraine
  • Innovations in Pharmaceutical Treatments
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Pharmaceutical, BY Type (USD Million)
      1. 4.1.1 Familial Hemiplegic Migraine
      2. 4.1.2 Sporadic Hemiplegic Migraine
    2. 4.2 Pharmaceutical, BY Treatment (USD Million)
      1. 4.2.1 Acute treatment
      2. 4.2.2 Triptans
      3. 4.2.3 Ergotamines
      4. 4.2.4 NSAIDs
      5. 4.2.5 Antiemetics
      6. 4.2.6 Narcotic Analgesics
      7. 4.2.7 Others
    3. 4.3 Pharmaceutical, BY End-user (USD Million)
      1. 4.3.1 Hospitals & Clinics
      2. 4.3.2 Diagnostic Centers
      3. 4.3.3 Others
    4. 4.4 Pharmaceutical, BY Preventive Treatment (USD Million)
      1. 4.4.1 Antidepressants
      2. 4.4.2 Botox Injections
      3. 4.4.3 Others
    5. 4.5 Pharmaceutical, BY Distribution Channel (USD Million)
      1. 4.5.1 Retail Pharmacies
      2. 4.5.2 Hospital Pharmacies
      3. 4.5.3 Online Pharmacies
      4. 4.5.4 Others
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Pharmaceutical
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Amgen (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Teva Pharmaceutical Industries (IL)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Eli Lilly and Company (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Novartis (CH)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Pfizer (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 AstraZeneca (GB)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Boehringer Ingelheim (DE)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Bristol-Myers Squibb (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TYPE
    3. 6.3 US MARKET ANALYSIS BY TREATMENT
    4. 6.4 US MARKET ANALYSIS BY END-USER
    5. 6.5 US MARKET ANALYSIS BY PREVENTIVE TREATMENT
    6. 6.6 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    7. 6.7 KEY BUYING CRITERIA OF PHARMACEUTICAL
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF PHARMACEUTICAL
    10. 6.10 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
    12. 6.12 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
    13. 6.13 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
    14. 6.14 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
    15. 6.15 PHARMACEUTICAL, BY TREATMENT, 2024 (% SHARE)
    16. 6.16 PHARMACEUTICAL, BY TREATMENT, 2024 TO 2035 (USD Million)
    17. 6.17 PHARMACEUTICAL, BY END-USER, 2024 (% SHARE)
    18. 6.18 PHARMACEUTICAL, BY END-USER, 2024 TO 2035 (USD Million)
    19. 6.19 PHARMACEUTICAL, BY PREVENTIVE TREATMENT, 2024 (% SHARE)
    20. 6.20 PHARMACEUTICAL, BY PREVENTIVE TREATMENT, 2024 TO 2035 (USD Million)
    21. 6.21 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    22. 6.22 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
      3. 7.2.3 BY END-USER, 2025-2035 (USD Million)
      4. 7.2.4 BY PREVENTIVE TREATMENT, 2025-2035 (USD Million)
      5. 7.2.5 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Hemiplegic Migraine Market Segmentation

US Hemiplegic Migraine Market By Type (USD Million, 2025-2035)

  • Familial Hemiplegic Migraine
  • Sporadic Hemiplegic Migraine

US Hemiplegic Migraine Market By Treatment (USD Million, 2025-2035)

  • Acute treatment
  • Triptans
  • Ergotamines
  • NSAIDs
  • Antiemetics
  • Narcotic Analgesics
  • Others

US Hemiplegic Migraine Market By End-user (USD Million, 2025-2035)

  • Hospitals & Clinics
  • Diagnostic Centers
  • Others

US Hemiplegic Migraine Market By Preventive Treatment (USD Million, 2025-2035)

  • Antidepressants
  • Botox Injections
  • Others

US Hemiplegic Migraine Market By Distribution Channel (USD Million, 2025-2035)

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.